Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Invivyd, Inc. - Common Stock (NQ: IVVD )

0.6702 -0.0312 (-4.45%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 598,293
Open 0.7196
Bid (Size) 0.6704 (2)
Ask (Size) 0.6998 (3)
Prev. Close 0.7014
Today's Range 0.6701 - 0.7500
52wk Range 0.6872 - 5.195
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor
From Invivyd
Via GlobeNewswire

Performance

YTD
-81.64%
-81.64%
1 Month
-31.20%
-31.20%
3 Month
-48.05%
-48.05%
6 Month
-61.92%
-61.92%
1 Year
-55.32%
-55.32%

More News

Read More
Earnings Outlook For Invivyd
Via Benzinga
Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to
From Invivyd
Via GlobeNewswire
Earnings Scheduled For November 14, 2024
Via Benzinga
Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference
From Invivyd
Via GlobeNewswire
Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024
From Invivyd
Via GlobeNewswire
This NANO Nuclear Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability
From Invivyd
Via GlobeNewswire
Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants
From Invivyd
Via GlobeNewswire
Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024
From Invivyd
Via GlobeNewswire
Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data
From Invivyd
Via GlobeNewswire
Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)
From Invivyd
Via GlobeNewswire
Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19
From Invivyd
Via GlobeNewswire
Invivyd to Participate in Upcoming Investor Conferences
From Invivyd
Via GlobeNewswire
Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™
From Invivyd
Via GlobeNewswire
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest
From Invivyd
Via GlobeNewswire
Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial
From Invivyd
Via GlobeNewswire
Why Keysight Technologies Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
Via Benzinga
IVVD Stock Earnings: Invivyd Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Invivyd Announces its Addition to the Russell 2000® and Russell 3000® Indexes
From Invivyd
Via GlobeNewswire
Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants
From Invivyd
Via GlobeNewswire
Invivyd to Participate at the Jefferies Global Healthcare Conference
From Invivyd
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.